Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ATRC 
AtriCure Inc (ATRC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: ATRC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $49.89
1 Year Target Price $49.89
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.68% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.57B USD | Price to earnings Ratio - | 1Y Target Price 49.89 |
Price to earnings Ratio - | 1Y Target Price 49.89 | ||
Volume (30-day avg) 9 | Beta 1.6 | 52 Weeks Range 20.20 - 43.11 | Updated Date 07/7/2025 |
52 Weeks Range 20.20 - 43.11 | Updated Date 07/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.95% | Operating Margin (TTM) -4.82% |
Management Effectiveness
Return on Assets (TTM) -3.7% | Return on Equity (TTM) -8.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1549802067 | Price to Sales(TTM) 3.28 |
Enterprise Value 1549802067 | Price to Sales(TTM) 3.28 | ||
Enterprise Value to Revenue 3.23 | Enterprise Value to EBITDA -135.97 | Shares Outstanding 49504900 | Shares Floating 47729112 |
Shares Outstanding 49504900 | Shares Floating 47729112 | ||
Percent Insiders 3.37 | Percent Institutions 103.6 |
Upturn AI SWOT
AtriCure Inc
Company Overview
History and Background
AtriCure, Inc. was founded in 2000. It is a medical device company focusing on developing, manufacturing, and selling innovative solutions for the treatment of atrial fibrillation and related conditions.
Core Business Areas
- Ablation Systems: Develops and markets radiofrequency (RF) ablation devices used to create lesions on heart tissue to treat atrial fibrillation.
- Left Atrial Appendage Management: Offers devices for occluding or excising the left atrial appendage (LAA) to reduce the risk of stroke in patients with atrial fibrillation.
- Open Heart Surgery: Also sells products for open heart surgery.
Leadership and Structure
Michael Carrel serves as the President and Chief Executive Officer. The company has a typical corporate structure with a board of directors and various functional departments.
Top Products and Market Share
Key Offerings
- CryoICE Cryoablation System: A cryoablation system used to create lesions on the heart. It competes with Medtronic, Boston Scientific, and Abbott. Market Share data is not publically available per product.
- AtriClip LAA Exclusion System: A clip used to occlude the left atrial appendage. This is a primary product, but specifics of market share and revenue are not publicly available. Competitors include Boston Scientific and Johnson & Johnson.
Market Dynamics
Industry Overview
The electrophysiology (EP) market is experiencing growth due to the increasing prevalence of atrial fibrillation and advancements in ablation technologies. The cardiac surgery market is also a large market and Atricure competes in different areas here.
Positioning
AtriCure is a key player in the atrial fibrillation ablation and left atrial appendage management market, known for its innovative ablation technologies and LAA exclusion devices. Their competitive advantage includes a focus on minimally invasive surgical approaches.
Total Addressable Market (TAM)
The total addressable market for AtriCure is estimated to be in the billions of dollars, encompassing atrial fibrillation ablation, LAA management, and pain management. AtriCure is positioned to capture a significant share of this market through its innovative products and focus on minimally invasive procedures.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Strong presence in the atrial fibrillation market
- Focus on minimally invasive procedures
- Established distribution network
Weaknesses
- Reliance on specific product lines
- Potential for product recalls
- Competition from larger medical device companies
Opportunities
- Expanding into new geographic markets
- Developing new products for related cardiac conditions
- Acquiring complementary technologies or businesses
Threats
- Increased competition from established players
- Changes in healthcare regulations
- Pricing pressures from hospitals and payers
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
- JNJ
Competitive Landscape
AtriCure competes with larger medical device companies with greater resources. AtriCure's advantage lies in its focus on specific areas of cardiac surgery and innovative product development.
Major Acquisitions
Estech Systems, Inc.
- Year: 2017
- Acquisition Price (USD millions): 36
- Strategic Rationale: Expand AtriCure's product portfolio in cardiac ablation technologies.
Growth Trajectory and Initiatives
Historical Growth: AtriCure has experienced growth driven by adoption of its ablation and LAA management products.
Future Projections: Future growth is projected based on continued adoption of existing products and the introduction of new innovations. Consult analyst reports for specific estimates.
Recent Initiatives: Recent initiatives include expanding clinical trials for new applications of their products and strategic partnerships.
Summary
AtriCure is a moderately strong company in the cardiac ablation and LAA management market. Its innovative product portfolio is a key strength, but it faces competition from larger players. Expanding geographically and developing new products offer significant growth opportunities while healthcare regulations and pricing pressures pose potential threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications, press releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AtriCure Inc
Exchange NASDAQ | Headquaters Mason, OH, United States | ||
IPO Launch date 2005-08-05 | CEO, President & Director Mr. Michael H. Carrel | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1300 | Website https://www.atricure.com |
Full time employees 1300 | Website https://www.atricure.com | ||
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.